

SmartPA Criteria Proposal

Drug/Drug Class:	Targeted Immune Modulators, Interleukin-6 (IL-6) Receptor Inhibitors PDL Edit
First Implementation Date:	January 22, 2004
Revised Date:	October 14, 2021
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Actemra® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist which inhibits endogenous IL-6 which initiates a variety of immunological responses. Inhibition of IL-6 decreases cytokine and acute phase reactant production. This agent is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults who have tried one or more disease-modifying anti-rheumatic drugs (DMARDs) and had an inadequate response, giant cell arthritis, severe or life-threatening cytokine release syndrome (CRS), and polyarticular juvenile idiopathic arthritis (PJIA) in those 2 years of age or older. Kevzara® (sarilumab), another IL-6 receptor antagonist, is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more DMARDs. Both agents are currently under investigation for the treatment of COVID-19 associated pulmonary complications with elevated IL-6 levels. These agents can lower the ability of the immune system to fight infections, so tuberculosis testing is recommended prior to initiating therapy. It is recommended to not initiate these agents if a participant has an absolute neutrophil count (ANC) is below 2000 per mm³ and/or if an ALT or AST greater than 1.5 times the upper limit of normal (ULN). It is also recommended to not initiate tocilizumab if a participant has a platelet count below 100,000 per mm³ and to not initiate sarilumab if a participant has a platelet count below 150,000 per mm³. Avoid administration of live vaccines when using these agents. Do not administer during an active infection and use caution in those who may be at an increased risk for developing gastrointestinal perforations.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Actemra® Syringe 	<ul style="list-style-type: none"> Actemra® ACTPen®/Vial Kevzara®

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Targeted Immune Modulators, Interleukin-6 (IL-6) Receptor Inhibitors
- Age range: All appropriate MO HealthNet participants aged 18 years or older unless indicated otherwise

Approval Criteria

- Documented compliance on current therapy **OR**
- Adequate therapeutic 6 month trial of tumor necrosis factor (TNF) inhibitors defined as:
 - Combination therapy of 2 TNF inhibitors **OR**
 - Monotherapy of 1 TNF inhibitor **AND**
- Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
 - Documented trial period of preferred agents (6 months of therapy) **OR**
 - Documented ADE/ADR to preferred agents **AND**
- For Actemra ACTPen and Vial: clinical consultant review for medical necessity **AND**
- Documented diagnosis of rheumatoid arthritis:
 - Adequate therapeutic trial of methotrexate **OR**
 - Contraindication to methotrexate therapy **OR**
- Documentation of appropriate diagnosis and participant age range for requested agent:

Generic	Brand	Indication
Sarilumab	Kevzara®	<ul style="list-style-type: none"> • Rheumatoid arthritis
Tocilizumab	Actemra® Actemra® ACTPen®	<ul style="list-style-type: none"> • Chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (aged 2 or older; approvable as first-line therapy without trial of TNF inhibitors) • Giant cell arteritis (approvable as first-line therapy without trial of TNF inhibitors) • Polyarticular juvenile idiopathic arthritis (aged 2 or older) • Rheumatoid arthritis • Systemic juvenile idiopathic arthritis (aged 2 or older)

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:

Progress Notes:

MedWatch Form:

Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

SmartPA PDL Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

References

1. USPDI, Micromedex; 2021.
2. Facts and Comparisons eAnswers (online); 2021 Clinical Drug Information, LLC.
3. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Singh et al. Arthritis Care & Research – DOI 10.1002/acr.22783
4. Evidence-Based Medicine Analysis: “Targeted Immune Modulators (Biologics – DMARDs)”. UMKC-DIC; April 2021.
5. Evidence-Based Medicine and Fiscal Analysis: “Targeted Immune Modulators: Selected/Miscellaneous Agents– Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; June 2021.
6. Actemra [package insert]. South San Francisco, CA: Genentech Inc; March 2021.
7. Kevzara [package insert]. Bridgewater, NJ: Sanofi Biotechnology; April 2018.